Privacy preference

MEDtalks would like to keep you informed about the content that is most relevant to you. Click here for more information.


Oncology News Program at Genitourinary Cancers Symposium 2015

The 2015 Genitourinary Cancers Symposium was held in Orlando from February 26th to 28th. In a multidisciplinary Oncology News Program Dutch and Belgian experts will discuss new important data, presented at this congress.

In the first part of this Oncology News Program Dr. Thierry Gil, Prof. Jeroen van Moorselaar and Dr. Fons van den Bergh talk about the role of Androgen Deprivation Therapy in early and intermediate risk prostate cancer, dose escalation in Radiotherapy, Stereotactic Body Radiotherapy and possible predictive markers like Slco2B1 and androgen receptor splice variant 7.

The second part covers the following topics on prostate cancer: Active Surveillance in early stage prostate cancer, Brachytherapy versus External Beam Radiation Therapy, active immunotherapy and check point inhibitors and one of the highlights of this congress, the GETUG-15 trial. These data are discussed by Prof. Winald Gerritsen, Prof. Gert De Meerleer and Prof. Thierry Roumeguère.

The panel for the last part of this Oncology News Program consists of Prof. Gerritsen, Prof. van Moorselaar and Prof. Roumeguère. The experts discuss important new data on GU-non prostate cancer: organ sparing versus radical cystectomy, (neo)adjuvant chemotherapy in bladder cancer, the role of profiling urothelial cancer, anti-PDL1 and Pazopanib in combination with Paclitaxel in refractory urothelial cancer.

Presented by dr. Ayan Panja.

  • Sponsors

    This program is editorially independent and is financially made possible by

Related items

Meet the author 17/12/2018

Quarterly Focus on Genitourinary Cancer: highlights in prostate cancer (part 2)

Publications in peer-reviewed journals are a major source for keeping up with the latest developments in your field. However, you may not always have sufficient time to study (difficult) publications thoroughly and to determine the impact on your clinical practice. To support you, MEDtalks Oncology has developed a new program format: the Quarterly Focus. This innovative program brings an expert panel and authors of relevant, selected publications together to explain and discuss the new data. In this third episode of the Quarterly Focus on Genitourinary Cancer, two pivotal, international publications on Bladder Cancer from the past few months will be clarified by one of the authors and will be thoroughly discussed by an expert panel including the author. The program will give you the possibility to gain more insight into the selected publications. The expert panel consist of: Niven Mehra, MD, PhD – medical oncologist, Radboudumc, Nijmegen Andre Bergman, MD, PhD – medical oncologist, Netherlands Cancer Institute, Amsterdam Prof. Theo de Reijke, MD - urologist, Amsterdam UMC, Amsterdam Program: Abiraterone plus Prednisone in Metastatic, Castration-Sensitive Prostate Cancer (LATITUDE) N Engl J M, July 27, 2017 Speaker: Karim Fizazi, MD, PhD - medical oncologist, Gustave Roussy Institute, Villejuif, France Radiotherapy to the primary tumour for newly diagnosed, metastatic prostate cancer (STAMPEDE): a randomised controlled phase 3 trial The Lancet, Oct 21, 2018 Speaker: Prof. Nicholas James, PhD - medical oncologist, University of Birmingham, UK

Congresnieuws 13/12/2018

EMUC 2018: POUT trial

Dr. Alison Birtle (UK) is thrilled about the results of the POUT trial. This trial examined the benefit of adjuvant chemotherapy after nephroureterectomy in patients with upper tract urothelial carcinoma.

Congresnieuws 13/12/2018

EMUC 2018: STAMPEDE trial

Prof. Nicholas James, oncologist at the University Hospitals Birmingham NHS Trust (UK), talks us through the new results of the STAMPEDE trial. Do the results of abiraterone differ in patients with high risk metastatic prostate cancer as compared to patients in the low risk category? And is there any benefit of adding radiotherapy to systemic therapy?

Congresnieuws 13/12/2018

EMUC 2018: Highlights

Prof. Alberto Briganti, professor in the urology at the IRCCS Ospedale San Raffaele in Italy, is a member of the EMUC scientific committee on behalf of the EAU. He shares with us his personal highlights of the EMUC 2018, among which are the STAMPEDE and HORRAD trials and new radiological developments.

Congresnieuws 13/12/2018

EMUC 2018: POTOMAC & ALBAN trials

Dr. Evanguelos Xylinas, urologist at Cochin Hospital, Paris Descartes University (France), is chief editor of the bladder cancer section of the UROONCO educational platform and talks about the POTOMAC trial (durvalumab plus BCG vs. BCG) and the ALBAN trial (atezolizumab plus BCG vs. BCG).

Congresnieuws 13/12/2018

EMUC 2018: Delaying metastasizing with enzalutamide or apalutamide

Can metastasizing of castration resistant prostate cancer be postponed by using enzalutamide or apalutamide? Dr. Karim Fizazi, medical oncologist at the Institut Gustave Roussy in France, concludes this is the case. Furthermore, he talks about the first results of darolutamide.

Congresnieuws 13/12/2018

EMUC 2018: HORRAD trial

In the HORRAD trial patients with prostate cancer were randomized to receive either local therapy and ADT or ADT alone. Dr. Liselotte Boevé, urologist at VU Medisch Centrum in Amsterdam, presents us the results.